In this study, we found that cfDNA from breast cancer cells not only could activate the TLR9-NF-κB pathway, but also increased the amount of p-ERα in HR+ breast cancer cells, ultimately increasing the abundance of cyclin D1. This evidence concerns the gene TLR9 and breast cancer.